From Early Adopter to Optimized Trials: Cara Therapeutics and Veeva Vault CDMS
From Early Adopter to Optimized Trials: Cara Therapeutics and Veeva Vault CDMS
3 Pages>50 % faster build times than original EDC provider From Early Adopter to Optimized Trials: Cara Therapeutics and Veeva Vault CDMS Clinical-stage biopharmaceutical company focused on the treatment of pruritus finds greater speed and flexibility in clinical trials with modern EDC. Success Highlights Greater CRF consistency and standardized trial data when working with CROs. Rapid post-production changes with zero migrations. Life as an Early Adopter Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing a novel class of peripherally acting kappa opioid agonist therapeutics with a primary focus for the treatment of pruritus and pain.
